Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
Rhea-AI Summary
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced its participation in the upcoming Citi 2025 Biopharma Back to School Conference. Rachel Haurwitz, PhD, the company's president and CEO, will engage in a fireside chat on September 3, 2025 at 2:30 PM EDT.
The presentation will be accessible through a webcast on Caribou's website's Events page and will remain available for at least 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction 7 Alerts
On the day this news was published, CRBU gained 6.38%, reflecting a notable positive market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $11M to the company's valuation, bringing the market cap to $188M at that time.
Data tracked by StockTitan Argus on the day of publication.
BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Citi 2025 Biopharma Back to School Conference on September 3, 2025 at 2:30 PM EDT.
For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on CB-010 and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow us @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
media@cariboubio.com
investor.relations@cariboubio.com
FAQ
When is Caribou Biosciences (CRBU) presenting at the Citi 2025 Biopharma Conference?
Who will represent Caribou Biosciences (CRBU) at the Citi 2025 Conference?
How can investors access Caribou Biosciences' (CRBU) conference presentation?
What type of company is Caribou Biosciences (CRBU)?
